Cancer Immunology, Immunotherapy

SJR Rank #1,736H-index: 148SJR: 1.805Best quartile: Q1Open AccessAPC: US$4,590Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Springer Science and Business Media Deutschland GmbH

Country

Germany

Type

journal

SJR by Edition

2022202500.511.52

Subject Categories

  • Cancer ResearchQ1
  • ImmunologyQ1
  • Immunology and AllergyQ1
  • Medicine (miscellaneous)Q1
  • OncologyQ1

Areas: Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine

Most published research topics

Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies ResearchImmune cells in cancerGlycosylation and Glycoproteins ResearchImmune Response and InflammationVirus-based gene therapy research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs02505007501000

Documents per Year

20222025095190285380

Detailed Information

ISSN

1432-0851, 0340-7004

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

5.56

References per Document

44.64

Coverage

1976-2026

Scope

Cancer Immunology, Immunotherapy has the basic aim of keeping readers informed of the latest research results in the fields of oncology and immunology. As knowledge expands, the scope of the journal has broadened to include more of the progress being made in the areas of biology concerned with biological response modifiers. This helps keep readers up to date on the latest advances in our understanding of tumor-host interactions. The journal publishes short editorials including "position papers," general reviews, original articles, and short communications, providing a forum for the most current experimental and clinical advances in tumor immunology.

Metrics from SCImago Journal Rank 2025. View on SCImago